Plus Therapeutics Inc (NASDAQ: PSTV) presented data from two ongoing trials of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), for recurrent glioblastoma (GBM) and leptomeningeal metastases.
The data from LM patients demonstrated that the 186RNL dose administered through an intraventricular catheter at 6.6 mCi in 5.0 mL achieved absorbed doses of 18.7 to 29.0 Gy, which were well tolerated with mild treatment-related adverse events.
Furthermore, all three patients in the cohort were observed to have prompt and complete 186RNL distribution throughout the cerebrospinal fluid (CSF) subarachnoid space that was durable past one week and very well tolerated.
All patients showed a decreased CSF cell count by microfluidic chamber assay after treatment, ranging from 65% to 92%, which was also durable.
Data also demonstrated that in 23 subjects with recurrent GBM receiving a single administration of 186RNL, significant overall survival benefits were observed in those achieving an average absorbed radiation dose greater than 100 Gy to the tumor compared to those with less absorption.
Data show that 186RNL treatment is safe and well-tolerated, with no adverse events (AEs) resulting in death or discontinuations.
Four patients remain alive. Cohort 7 of the trial, with an increased dose of 186RNL, is currently enrolling.
Price Action: PSTV shares are up 82.5% at $0.96 during the premarket session on the last check Monday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.